Wien Energie and RIDDLE&CODE successfully establish one of the first peer-to-peer (P2P) energy trading communities in Europe
17.12.2020 12:30:00 EET | Business Wire | Press release
Wien Energie, Austria’s largest regional energy services provider, and RIDDLE&CODE are proud to announce the successful completion of the ‘Peer2Peer im Quartier’ project that empowers consumers to co-create the future of energy and accelerates the transition to renewable electricity sources.
Viertel Zwei, the modern residential and office location in Vienna, Austria, has been the site of a multi-year project since 2018, with blockchain technology playing a central role. Together with the residents of Viertel Zwei, the two companies developed a smart network of utility providers, grids and consumers to create one of the first P2P energy trading communities in Europe.
“RIDDLE&CODE developed blockchain-based extension that establishes a tamper-proof identity for all devices related to the production and consumption of energy and transforms them into trusted data sources that perform value transactions and settlements,” the Founder and CTO of RIDDLE&CODE, Thomas Fuerstner, said.“This project allows RIDDLE&CODE and Wien Energie to accelerate the progress toward the new era of energy distribution in which consumers and energy providers work together to create a more resilient, reliable and localised energy network.”
"With our energy community project in Viertel Zwei we have been able to implement the Blockchain technology in a consumers context for the first time. We are proud that we are pioneers in this field and that we have successfully accomplished this trading attempt together with RIDDLE&CODE. In the future, Blockchain can play an essential role in the energy industry. The knowledge gained here will be an important cornerstone for further joint projects", Michael Strebl, CEO of Wien Energie, added.
With a blockchain-powered photovoltaic system on the roof of their complex, residents of Viertel Zwei can trade, share or resell the electricity they produce to other residents within the community, monitor their consumption and manage tariffs using a convenient online platform.
RIDDLE&CODE and Wien Energie will not stop there. Together with the Austrian Research Promotion Agency, a research report with the insights from the project will be published in early 2021. Among other topics, the report will explore the benefits of P2P energy trading for consumers and utility providers and the development of new types of markets, such as distributed, local and micro energy markets.
About Wien Energie
Wien Energie is Austria’s largest regional energy services provider, providing two million people, approximately 230,000 businesses, industrial facilities and public buildings, as well as around 4,500 farms with electricity, natural gas, heat, district cooling and innovative energy services. Wien Energie produces electricity and heat from renewable energy sources, thermal waste recycling and high- efficiency cogeneration power plants. The company is also active in the field of telecommunications and provides additional energy and infrastructure services.
About RIDDLE&CODE
RIDDLE&CODE is the leading European blockchain interface company that builds hardware and software stacks and brings trusted identity to objects and people. Together with its tier-one clients and partners, RIDDLE&CODE creates new business models for financial markets, energy distribution, mobility and the Internet of Things.
For more information: www.riddleandcode.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005056/en/
Contact information
Media contact:
Aysenur Yükselal Aji
aysenur@riddleandcode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom